<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01480869</url>
  </required_header>
  <id_info>
    <org_study_id>VITACAL</org_study_id>
    <secondary_id>VA 2010/12</secondary_id>
    <secondary_id>2010-023459-27</secondary_id>
    <nct_id>NCT01480869</nct_id>
  </id_info>
  <brief_title>Study of Vitamin D Supplementation Tailored to Vitamin D Deficiency in Breast Cancer Patients</brief_title>
  <acronym>VITACAL</acronym>
  <official_title>Randomized Phase III Trial Comparing Conventional Vitamin D Supplementation vs. Vitamin D Supplementation Tailored to Vitamin D Deficiency in Breast Cancer Patients Treated by Neoadjuvant or Adjuvant Chemotherapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut du Cancer de Montpellier - Val d'Aurelle</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut du Cancer de Montpellier - Val d'Aurelle</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare normalization of vitamin D serum level after 6 months
      of vitamin D supplementation adjusted to baseline vitamin D serum level vs.conventional
      vitamin D supplementation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the increase in normalization of serum vitamin D level</measure>
    <time_frame>6 months</time_frame>
    <description>To compare the increase in normalization of serum vitamin D level adjusted to baseline level in patients receiving either vitamin D supplementation tailored to vitamin D deficiency or conventional vitamin D supplementation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Baseline vitamin D/calcium status in this patient population</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normalization rate of serum 25-OHD level</measure>
    <time_frame>12, 18 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normalization rate of serum 25-OHD level in control patients who shift to experimental strategy</measure>
    <time_frame>6 months after crossover</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical and biological tolerance profile</measure>
    <time_frame>During treament administration (can last up to 24 months)</time_frame>
    <description>According to National Cancer Institute-Common Terminology Criteria for Adverse Events Version 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment compliance</measure>
    <time_frame>During treatment administration (can last up to 24 months)</time_frame>
    <description>Treatment compliance will be assessed using a patient record book</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>24 months</time_frame>
    <description>Quality of life is assessed using the EORTC QLQ-C30 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of study treatments on bone and joint pains induced by aromatase inhibitors</measure>
    <time_frame>During treatment administration (can last up to 24 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in vitamin and calcium biological markers</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictive value of individual biomarkers</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">264</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Conventional vitamin D and calcium supplementation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional vitamin D and calcium supplementation with 2 daily OROCAL VITAMINE D3® (500 mg calcium/200 IU cholecalciferol) tablets.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vitamin D supplementation tailored to vitamin D deficiency</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conventional calcium supplementation with 2 daily OROCAL 500® (500 mg calcium) tablets to suck + vitamin D3 supplementation (UVÉDOSE®, cholecalciferol, 100 000 IU drinkable solution, 2 ml vial) whose schedule of administration depends on vitamin deficiency level:
100 000 IU of vitamin D3 at D1, D15, D28 and D43 if 25OHD level &lt; 10 ng/mL
100 000 IU of vitamin D3 at D1, D15, D28 if 10 ng/mL ≤ 25OHD level &lt; 20 ng/mL
100 000 IU of vitamin D3 at D1 if 20 ng/mL ≤ 25OHD level &lt; 30 ng/mL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>calcium and cholecalciferol</intervention_name>
    <description>Tablet to suck: calcium 500 mg bid, cholecalciferol 200 IU bid</description>
    <arm_group_label>Conventional vitamin D and calcium supplementation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>calcium and cholecalciferol</intervention_name>
    <description>Tablet: calcium 500 mg bid + 2 ml drinkable solution cholecalciferol 100 000 IU whose schedule of administration depends on vitamin deficiency level:
100 000 IU of vitamin D3 at D1, D15, D28 and D43 if 25-OHD level &lt; 10 ng/mL
100 000 IU of vitamin D3 at D1, D15, D28 if 10 ng/mL ≤ 25-OHD level &lt; 20 ng/mL
100 000 IU of vitamin D3 at D1 if 20 ng/mL ≤ 25-OHD level &lt; 30 ng/mL</description>
    <arm_group_label>vitamin D supplementation tailored to vitamin D deficiency</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Breast adenocarcinoma treated by neoadjuvant or adjuvant chemotherapy within 12 months
             prior to study enrollment

          -  WHO performance status 0-1

          -  Age ≥18 years old

          -  Affiliation to a social security regime or beneficiary of equivalent social protection

          -  Written informed consent provided before any study specific procedures

        Complementary inclusion criterion for randomization

        - Proved vitamin D deficiency as defined by serum vitamin D level lower than 30 ng/ml (75
        nmol/L).

        Exclusion Criteria:

          -  Metastatic disease

          -  History or presence of any other malignancy (except curatively treated nonmelanoma
             skin cancer or in situ cervix carcinoma) ………….

        traités dans les 5 ans précédents.

          -  Contraindication to calcium or cholecalciferol

          -  Known severe hypersensitivity to vitamin D or to calcium supplementation or to one of
             the excipients.

          -  Disease and/or medical conditions accompanied by hypercalcaemia and/or hypercalciuria

          -  Calcium lithiasis and tissue calcification

          -  Hypervitaminosis D

          -  Presence of significant comorbidities:

             i) Uncontrolled endocrine disease ii) Known disorders of calcium phophorus laboratory
             testing iii) Proved osteopenia or osteoporosis requiring vitamin D and calcium
             supplements

          -  Concomitant treatment with other experimental products or another vitamin D calcium
             treatment

          -  Pregnancy, breastfeeding or of reproductive potential not using an effective
             contraceptive method

          -  Legal inability or restricted legal ability. Medical or psychological conditions not
             allowing proper study completion or informed consent signature
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CRLC Val d'Aurelle-Paul Lamarque</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2011</study_first_submitted>
  <study_first_submitted_qc>November 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2011</study_first_posted>
  <last_update_submitted>July 29, 2015</last_update_submitted>
  <last_update_submitted_qc>July 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Vitamin D supplementation</keyword>
  <keyword>in neoadjuvant</keyword>
  <keyword>adjuvant setting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

